Overview
Lutetium Lu 177 vipivotide tetraxetan, marketed under the brand name Pluvicto, received approval from the U.S. Food and Drug Administration (FDA) on March 23, 2022, for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor pathway inhibition and taxane-based chemotherapy. This drug aims at developing prostate cancer cells with radioactive elements that help emit radiation to kill cancerous cells. This is so because it has certain radioactive properties, and therefore, it can only be provided by Nuclear Medicine specialists.
Drug Group
Lutetium Lu 177 vipivotide tetraxetan is a radiopharmaceutical. It also finds application as a radiolabeled peptide towards targeted therapy. Sometimes, it is grouped into a large group of radiation oncology agents, which use radiation to destroy cancerous cells.
Dosage Forms and Strengths
-
Form: Liquid state.
-
Strength: 1,000 MBq/mL or megabecquerels per milliliter (27 mCi/mL or millicuries per milliliter)
-
Administration: IV (intravenous) injection, administered at six weekly intervals, with a maximum of six doses depending on the effect or side effects in the case of the patients.
For Patients:
Indications
For Patients With MCRPC: Lu 177 vipivotide tetraxetan is used in patients with metastatic prostate cancer resistance to previous androgen receptor pathway inhibitors and chemotherapy drugs in the taxane group among patients whose tumors express the prostate-specific membrane antigen (PSMA).
Contraindication
-
Lutetium Lu 177 vipivotide tetraxetan is contraindicated in the following situations:
-
Existing chemicals are hypersensitive to the drug or its components.
-
Renal or hepatic disease of extreme severity because of possible toxicity.
-
Pregnancy and breastfeeding since there can be radiation risks.
-
Continued on or severe bone marrow depression from the disease process.
-
Patients with severe cardiovascular (heart) disease should be more careful.
Patients need to be properly assessed to avert any complications or other side effects of these CDD conditions.
Limitations of Lutetium Lu 177 Vipivotide Tetraxetan:
Lutetium Lu 177 vipivotide tetraxetan is effective for neuroendocrine tumors that have somatostatin receptors and is somewhat limited. It also exposes the patient to radiation, which can also affect healthy tissues and cells; it is contraindicated where the patient has renal or liver diseases.
Possible Side Effects Are as Follows:
The risk of organ toxicity cannot be excluded. Even though the treatment can stop the development of the tumor, it does not eliminate it completely, and long-term results have been reported. Furthermore, it is more expensive than many other drugs and is not available to everybody, for instance, many patients. The following with regard to his use should be considered.
How Is Lutetium Lu 177 Vipivotide Tetraxetan Used for Prostate Cancer?
Lutetium Lu 177 vipivotide tetraxetan is not applicable in prostate cancer altogether. However, it can be used in certain conditions if the cancer cells of the prostate have somatostatin receptors. This is especially true in the metastatic prostate cancer with specific molecular features. The drug affects the tumor cells and has a radiosensitizing effect; that is, it brings shrinkage of the tumor or rates of its development.
Lutetium Lu 177 vipivotide tetraxetan would be specifically applied to patients in the later stages of prostate cancer, which has either progressed or recurred despite optimal management. It could possibly be used in those with hormone-refractory prostate cancer that have the reception to hormone treatment or chemotherapy.
However, its use has not been approved yet, and the therapy is not considered the standard of care for prostate cancer currently.
How Should Lutetium Lu 177 Vipivotide Tetraxetan Be Used?
Lutetium Lu 177 vipivotide tetraxetan and this interim analysis of this clinical trial should be given by a healthcare provider proficient in radiopharmaceuticals. It is administered by an intravenous infusion, and the typical dose depends on the patient’s weight and the tumor. Appropriate investigations are required before the somatostatin receptor expression in the tumors can be confirmed. The medication is normally administered in cycles with a frequent evaluation of the effects, including kidney and liver toxicity. Additional measures, including the use of pre-therapy hydration and kidney protective measures, may be required. Because of its radiation element, the drug should only be administered in special centers so that patients and healthcare givers are not affected.
What Are the Side Effects of Lutetium Lu 177 Vipivotide Tetraxetan?
Common side effects include:
-
Gastrointestinal: N/V (nausea and vomiting), xerostomia (dry mouth), diarrhea, constipation
-
Systemic: Gastrointestinal disturbances mainly include loss of appetite, weight loss, fatigue, and headache.
Serious side effects not frequently reported include:
-
Blood-related: Unusual bruising or bleeding, anemia (low red blood cell count), fatigue, pallor.
-
Kidney Toxicity: Close testing of the kidney’s condition is needed.
-
Infections and Fever: Due to immunosuppression (reduction or weakening of the immune system's ability to fight infections and diseases).
What Are the Things to Inform the Doctor Before Taking Lutetium Lu 177 Vipivotide Tetraxetan?
Before taking Lutetium Lu 177 vipivotide tetraxetan, it is important to inform your doctor about the following:
-
Allergies: Let your doctor know if you are allergic to Lutetium Lu 177 vipivotide tetraxetan or any of its components so as to avoid allergic reactions.
-
Kidney and Liver Function: Inform your doctor if you have kidney or liver problems because the drug may not be suitable for people with serious conditions.
-
Current Medications: A list of all medications prescribed, medications taken without prescription, and supplements since these may interfere with the efficacy of the drug.
-
Pregnancy and Breastfeeding: If pregnant or planning on becoming pregnant or breastfeeding, then consult your doctor, as it has side effects that may interact with the fetus or infant through radiation.
Overdose: If you suppose that you have taken an overdose, it is required to address a healthcare provider. Adverse effects of overdose may be an increased radiation dose that would be toxic or have severe side effects. In regards to any cases of overdose, your doctor will do everything possible in reference to handling the issue.
Missed Dose: If you have forgotten to take the dose, contact your healthcare provider. The dosage plan should be followed to the letter because missing some doses may compromise the entire therapy.
Other Health Conditions: Tell your doctor if you have chronic active infections, blood disorders, or other severe diseases that might interfere with the treatment.
Sharing this information will allow your doctor to achieve the best results of the treatment without the risks associated with your particular health conditions.
Storage and Disposal:
-
Storage: Keep at room temperature (20°Celsius to 25°Celsius) 68 degree Fahrenheit to 77 degrees Fahreinheit, shielded from moisture and excessive heat, and stored in radiation-protected containers.
-
Disposal: Dispose of through licensed radioactive waste services, following local regulations. Use appropriate protective gear to prevent radiation exposure.
For Doctors
Clinical Pharmacology of Lutetium Lu 177 Vipivotide Tetraxetan
Lutetium Lu 177 vipivotide tetraxetan is an anti-cancer agent in targeted radiopharmaceutical therapy administrated for cancer cells with somatostatin receptors. It is intended to give a specific amount of radiation to malignant cells with less harm to other parts of the body.
Mechanism of Action
Lutetium Lu 177 vipivotide tetraxetan acts through the interaction with somatostatin receptors, which are present on the outer membrane of various tumor cells, including those of neuroendocrine origin. It then gets internalized in the tumor cell after it has bound to the receptor on the surface of the cell. The gamma-safe radioactive isotope is bonded with Lutetium-177, and it emits beta radiation that kills the cancer cells as it destroys its DNA (deoxyribonucleic ccid). This targeted radiation exposure approach assists in reducing harm to any well tissues and yet provides a strong treatment for the cancer.
Pharmacodynamics:
Lutetium Lu 177 vipivotide tetraxetan is an sst-receptor-targeted somatostatin analog used selectively for sst-positive tumor cells, which emit radiation that can damage the tumor DNA, halt the growth and cause regression of the tumors. It is mainly employed in tumors that express high levels of somatostatin receptors and thus spare most of the adjacent tissues. It may also stimulate the immune systems in the tumor.
Pharmacokinetics:
Following intravenous injection, Lutetium Lu 177 vipivotide tetraxetan rapidly accumulates in somatostatin receptor-positive tumors and shows a long half-life. The drug is only metabolized to a small extent, and the major percentage is eliminated through the kidneys. Pharmacokinetics such as clearance and half-time of the drug are influenced by kidney function, and therefore patients should be well hydrated and renal function well protected to avoid nephrotoxicity. Consistent follow-up and dosage adjustments are essential to maintain the highest efficacy and lowest side effects.
Drug Warnings and Precautions
-
Radiation Exposure: You should not embrace or touch anyone and should avoid pregnant women and children for some prescribed days after treatment.
-
Kidney and Bone Marrow Toxicity: Myelosuppression, which compromises various cell lines, and renal toxicity, is a prominent risks.
-
Infertility: This treatment can lead to sterility; thus, patients who may want to have children can preserve sperm.
-
Embryo-Fetal Toxicity: The medication is dangerous to a developing fetus, and male patients must use protection for 14 weeks post-treatment.
Clinical Studies
Lutetium Lu 177 vipivotide tetraxetan is known to have undergone analysis within clinical trials for the treatment of patients with neuroendocrine tumors sensitive to somatostatin receptors receptor. These studies have demonstrated that it can cause the tumor to shrink, prevent the cancer from advancing, and prolong PFS in the group of patients who are otherwise untreated by conventional therapies. The drug is effective in providing symptomatic relief from pain and also improves the quality of life of the patients, but the side effects include fatigue and renal toxicity. Therefore, the current work in progress is directed towards strengthening its safety profile and defining its most effective application, with particular attention to the possibility of using it concomitantly with other treatments. Lutetium 177 prostate cancer treatment has gained attention as a promising option, particularly when combined with PSMA-targeted therapy, which allows precise delivery of treatment to prostate-specific membrane antigen-expressing cancer cells.
Use in Specific Populations
Pregnancy:
Lutetium Lu 177 vipivotide tetraxetan should not be prescribed to pregnant women on account of the potential dangers posed by radiation to a developing fetus. It belongs to pregnancy category X and may harm the fetus or result in fetal death. Patients of childbearing potential must avoid conception during treatment and while receiving the drug, and if pregnant or suspecting they are pregnant, there should be consideration of other forms of treatment.
Lactation:
Lutetium Lu 177 vipivotide tetraxetan is contraindicated in patients who are breastfeeding as this exposes the infant to radiation. Lactation should be avoided before the initiation of the treatment and not continued after it, as the medication is present in breast milk and may be toxic to the baby. It may be important to chat with a healthcare provider about other feeding options.
Pediatric Population:
The lack of safety and efficacy of Lutetium Lu 177 vipivotide tetraxetan for pediatrics is unknown, and therefore, the product is contraindicated in children. Decisions as to the treatment should take into account other therapies that are appropriate for this age group.
Renal and Hepatic Impairment:
Contraindicated in patients with severe renal or hepatic impairment of hepatic function and requires caution when administering a treatment regimen. The drug is primarily metabolized in the kidneys and liver; hence, patients with compromised renal or hepatic function are likely to develop toxicity associated with the drug. The patient should remain on a renal protective agent, and kidney and liver function should be monitored appropriately during treatment.
Geriatric Population:
Lutetium Lu 177 vipivotide tetraxetan should be administered carefully to elderly patients, especially those with a history of renal or hepatic disease. Compliance may also be an issue, owing to factors such as age-relevant changes in organs’ function that might alter the metabolism of the medicinal product, coupled with the fact that older learners are generally more likely to suffer side effects. The use of dose adjustments and applications of the ‘once daily’ principle is essential in case the safety and efficacy of the medicine are to be achieved.
